<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621772</url>
  </required_header>
  <id_info>
    <org_study_id>DJ_PD_21_02</org_study_id>
    <nct_id>NCT05621772</nct_id>
  </id_info>
  <brief_title>Meridian Activation Remedy System for Parkinson's Disease</brief_title>
  <acronym>MARS-PD</acronym>
  <official_title>MARS-PD: Meridian Activation Remedy System for Parkinson's Disease - A Single-center, Rater-blinded, Parallel Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Health Industry Development Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Health Industry Development Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators aim to evaluate the clinical efficacy and cost-effectiveness&#xD;
      of MARS-PD. Conventional, usual care will be used as the comparator because this trial aims&#xD;
      to assess the add-on effect of MARS-PD. The investigators hypothesize that the complex&#xD;
      therapy will relieve motor and nonmotor symptoms, improve gait performance, and enhance&#xD;
      neuroplasticity in PD patients, and will be safe and cost-effective.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Single-center, Rater-blinded, Parallel Randomized Controlled Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Movement Disorder Society Unified Parkinson's Disease Rating Scale Part Ⅲ</measure>
    <time_frame>Change from baseline MDS-UPDRS Part Ⅲ score at 8 weeks</time_frame>
    <description>MDS-UPDRS Part Ⅲ (maximum: 132, minimum: 0; higher scores mean a worse outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Movement Disorder Society Unified Parkinson's Disease Rating Scale Part Ⅲ</measure>
    <time_frame>Change from baseline MDS-UPDRS Part Ⅲ score at 4 and 12 weeks</time_frame>
    <description>MDS-UPDRS Part Ⅲ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire Short Form</measure>
    <time_frame>Change from baseline IPAQ score at 4, 8 and 12 weeks</time_frame>
    <description>IPAQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson Self Questionnaire</measure>
    <time_frame>Change from baseline Parkinson Self Questionnaire results at 4, 8 and 12 weeks</time_frame>
    <description>Parkinson Self Questionnaire, developed by researchers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's disease Sleep Scale</measure>
    <time_frame>Change from baseline PDSS score at 4, 8 and 12 weeks</time_frame>
    <description>PDSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed up and go test</measure>
    <time_frame>Change from baseline TUG time in seconds at 8 and 12 weeks</time_frame>
    <description>TUG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAITRite Electronic Walkway Platinum</measure>
    <time_frame>Change from baseline GAITRite parameters at 8 and 12 weeks</time_frame>
    <description>GAITRite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional near-infrared spectroscopy</measure>
    <time_frame>Change from baseline fNIRS results at 8 and 12 weeks</time_frame>
    <description>fNIRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smart band outcomes</measure>
    <time_frame>Change from baseline daily steps at 4, 8 and 12 weeks</time_frame>
    <description>Number of steps per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iris imaging 1</measure>
    <time_frame>Iris connective tissue texture, baseline</time_frame>
    <description>Visible light image</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iris imaging 2</measure>
    <time_frame>Iris connective tissue density, baseline</time_frame>
    <description>Infrared image</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Experimental group (Meridian Activation Remedy System for Parkinson's Disease)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meridian Activation Remedy System for Parkinson's Disease (MARS-PD) treatment (16 times/8 weeks total, 2 times/week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (Usual Care)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care (all participants will be allowed to continue their prescribed medication and treatment (except Korean Medicine therapy), and they will not receive any additional treatment or therapy in the research institute), and lifestyle advice (all participants will receive a smart band and application-based guidance about their lifestyle)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Meridian Activation Remedy System for Parkinson's Disease (MARS-PD)</intervention_name>
    <description>MARS-PD is a complex therapy developed by researchers to enhance the synergistic effects of acupuncture and exercise.</description>
    <arm_group_label>Experimental group (Meridian Activation Remedy System for Parkinson's Disease)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 45 to 75 years of age&#xD;
&#xD;
          2. Patients with PD, diagnosed according to the United Kingdom Parkinson's Diseases&#xD;
             Society Brain Bank Criteria&#xD;
&#xD;
          3. Hoehn and Yahr scale stage I to III&#xD;
&#xD;
          4. Patients who have voluntarily decided to participate in the clinical study and signed&#xD;
             the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically unstable patients (e.g., elevated aspartate transaminase (AST) or alanine&#xD;
             aminotransferase (ALT) more than three-fold the upper limit of normal in the research&#xD;
             institute's laboratory, heart failure, respiratory failure, etc.)&#xD;
&#xD;
          2. Patients who are planning to undergo deep brain stimulation within the study period&#xD;
&#xD;
          3. Pregnant or lactating women&#xD;
&#xD;
          4. Patients with MMSE-K (Mini-Mental State Exam) score of 18 or less&#xD;
&#xD;
          5. If there has been a change in the dosage of antiparkinsonian drugs (e.g., L-dopa, COMT&#xD;
             (catechol-O-methyltransferase) inhibitor, Dopamine agonist, MAO-B (monoamine oxidase&#xD;
             B) inhibitor, etc.) according to a doctor's prescription within the last 4 weeks prior&#xD;
             to enrollment&#xD;
&#xD;
          6. Patients who are receiving manual therapy, exercise therapy, or rehabilitation therapy&#xD;
             for Parkinson's disease according to a doctor's prescription within the last 4 weeks&#xD;
             prior to enrollment, or are planning to receive such therapy within the study period&#xD;
&#xD;
          7. Patients who are not suitable for participation in this clinical study according to&#xD;
             the judgment of the researcher&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho Ryong Yoo, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daejeon University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miso S. Park, Dr.</last_name>
    <phone>+82-42-470-9555</phone>
    <email>miso.sophia.park@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ho Ryong Yoo, Prof. Dr.</last_name>
    <phone>+82-42-470-9131</phone>
    <email>hryoo@dju.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Trial Center, Daejeon Korean Medicine Hospital of Daejeon University</name>
      <address>
        <city>Daejeon</city>
        <zip>35235</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miso S. Park, Dr.</last_name>
      <phone>+82-42-470-9555</phone>
      <email>miso.sophia.park@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 17, 2022</last_update_submitted>
  <last_update_submitted_qc>November 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Daejeon University</investigator_affiliation>
    <investigator_full_name>HoRyong Yoo</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

